Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Pfizer Inc.
Expert Illustrations & Commentaries™: Roles and Rationales for BCMA-Directed Therapies in Multiple Myeloma
Release Date: December 23, 2021
Expiration Date: December 23, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Pfizer Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the rationale for targeting BCMA in R/R MM and the mechanisms of action for therapeutic agents acting through BCMA
- Assess pivotal trials’ results from studies that evaluated current and emerging BCMA-targeted agents evaluated for the treatment of patients with R/R MM
- Implement strategies to promptly identify and mitigate toxicities associated with agents targeting BCMA in R/R MM
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Faculty

Professor of Medicine
Program Director
Center for Multiple Myeloma
Massachusetts General Hospital
Boston, MA
Disclosures: Grant/Research Support: bluebird bio; Consultant: Celgene, Takeda, Amgen, Bristol Myers Squibb, Karyopharm Therapeutics

Professor of Medicine
Director, Multiple Myeloma Program
Duke Cancer Institute
Durham, NC
Disclosures: Consultant: AbbVie, GlaxoSmithKline, Karyopharm Therapeutics, Sanofi; Speaker’s Bureau: Bristol Myers Squibb, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.